Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.
Vincenzo RussoGaetano PiccinocchiVincenzo MandalitiSaverio AnnunziataGiovanni CimminoEmilio AttenaNicola MoioPierpaolo Di MiccoSergio SeverinoRoberta TrottaMichele Del GuercioPublished in: International journal of environmental research and public health (2020)
Our data show a high prevalence of hypertension, more likely treated with renin-angiotensin-aldosterone system (RASS) inhibitors, among COVID-19 patients not requiring hospitalization. Experimental COVID-19 therapies have been prescribed to COVID-19 patients considered at risk for increased venous thromboembolism based on concomitant comorbidities, in particular diabetes and hypertension.
Keyphrases
- sars cov
- venous thromboembolism
- blood pressure
- angiotensin ii
- angiotensin converting enzyme
- respiratory syndrome coronavirus
- type diabetes
- cardiovascular disease
- electronic health record
- direct oral anticoagulants
- big data
- adipose tissue
- atrial fibrillation
- data analysis
- skeletal muscle
- arterial hypertension
- deep learning